Identification of a Novel Estrogen-Regulated Gene, EIG121, Induced by Hormone Replacement Therapy and Differentially Expressed in Type I and Type II Endometrial Cancer
暂无分享,去创建一个
G. Stancel | R. Broaddus | G. Shipley | L. Deng | P. Davies | J. Pickar | A. McCampbell | D. Loose
[1] P. Boyle,et al. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. , 2004, Gynecologic oncology.
[2] V. Bae-Jump,et al. Uterine serous and grade 3 endometrioid carcinomas , 2004, Cancer.
[3] A. Niveleau,et al. Correlation between the DNA global methylation status and progesterone receptor expression in normal endometrium, endometrioid adenocarcinoma and precursors , 2004, Virchows Archiv.
[4] S. Lax. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification , 2004, Virchows Archiv.
[5] G. Stancel,et al. Coordinate regulation of the production and signaling of retinoic acid by estrogen in the human endometrium. , 2003, The Journal of clinical endocrinology and metabolism.
[6] Brady J. McKee,et al. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer? , 2002, International journal of radiation oncology, biology, physics.
[7] G. Parham,et al. Overexpression of HER-2/neu in uterine serous papillary cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] J. Bolton,et al. Oxidative DNA damage induced by equine estrogen metabolites: role of estrogen receptor alpha. , 2002, Chemical research in toxicology.
[9] A. García,et al. Molecular pathology of endometrial hyperplasia and carcinoma. , 2001, Human pathology.
[10] D. Purdie,et al. Epidemiology of endometrial cancer. , 2001, Best practice & research. Clinical obstetrics & gynaecology.
[11] R. Bentley,et al. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. , 2000, Gynecologic oncology.
[12] R. Slebos,et al. The frequency of p53, k‐ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma , 2000, Cancer.
[13] J. Boyd,et al. Causes and consequences of microsatellite instability in endometrial carcinoma. , 1999, Cancer research.
[14] Kathleen R. Cho,et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. , 1997, Cancer research.
[15] M. Koshiyama,et al. Expression of ps2 protein in endometrial carcinomas: Correlation with clinicopathologic features and sex steroid receptor status , 1997 .
[16] M. Sherman,et al. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. , 1995, Human pathology.
[17] E. Milgrom,et al. Control of biosynthesis and post-transcriptional modification of the progesterone receptor. , 1992, Biology of reproduction.
[18] E. Milgrom,et al. Characterization of the hormone responsive element involved in the regulation of the progesterone receptor gene. , 1991, The EMBO journal.
[19] B. Scheithauer,et al. Clinicopathologic analysis of uterine malignant mixed müllerian tumors. , 1989, Gynecologic oncology.
[20] R. Kurman,et al. The behavior of endometrial hyperplasia. A long‐term study of “untreated” hyperplasia in 170 patients , 1985 .
[21] P. Chambon,et al. Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[22] J. V. Bokhman. Two pathogenetic types of endometrial carcinoma. , 1983, Gynecologic oncology.
[23] R. Kempson,et al. Uterine papillary serous carcinoma: A highly malignant form of endometrial adenocarcinoma , 1982, The American journal of surgical pathology.
[24] Thompson Mh,et al. Oestrogens and endometrial hyperplasia. , 1980 .
[25] P. Stolley,et al. Endometrial cancer and estrogen use. Report of a large case-control study. , 1979, The New England journal of medicine.
[26] W. O'Fallon,et al. Exogenous estrogen and endometrial carcinoma: case-control and incidence study. , 1977, American journal of obstetrics and gynecology.
[27] D. Thompson,et al. Association of exogenous estrogen and endometrial carcinoma. , 1975, The New England journal of medicine.
[28] Ralph,et al. A Clinicopathologic Study , 2006 .
[29] A. Jemal,et al. Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.
[30] Amir Jazaeri,et al. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. , 2003, Cancer research.
[31] I. Bukovsky,et al. Uterine papillary serous carcinoma (pure and mixed type) compared with moderately and poorly differentiated endometrioid carcinoma. A clinicopathologic study. , 2002, European journal of gynaecological oncology.
[32] R. Kurman,et al. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. , 1997, Verhandlungen der Deutschen Gesellschaft fur Pathologie.
[33] S. Silverberg. Mixed müllerian tumors. , 1992, Current topics in pathology. Ergebnisse der Pathologie.
[34] R. Kurman,et al. The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients , 1986 .
[35] J. Studd,et al. Oestrogens and endometrial hyperplasia. , 1980, British journal of hospital medicine.
[36] P. Chambon,et al. Activation of pS 2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7 ( nuclear run-on transcription / cycloheximide / steroid hormone / gene expression / induction ) , 2022 .